Gaston-Dreyfus Remi's Form 4 filing
Bionik Laboratories Corp. (BNKL) · filed Jun 21, 2023
- Accession no.
- 0001104659-23-073229
- Filed
- Jun 21, 2023
- Trade date
- Jun 9, 2023
- Filing delay
- 12 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $108.3K. It was filed 12 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gaston-Dreyfus RemiCIK 0001716639 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 9, 2023 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +180,555 | $0.60F1 | +$108,333 | 1,814,871 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reporting person acquired the shares of common stock in lieu of cash payment of $108,333 in accrued and unpaid fees relating to reporting person's services as a director of the Issuer.
Referenced by the price of 1 transaction in Table I.